Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：160頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014’, provides an overview of the Cytomegalovirus (HHV-5) Infections’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cytomegalovirus (HHV-5) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014’, provides an overview of the Cytomegalovirus (HHV-5) Infections’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cytomegalovirus (HHV-5) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cytomegalovirus (HHV-5) Infections Overview 8
Therapeutics Development 9
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 9
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 10
Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 11
Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 14
Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 20
Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 22
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 23
Vical Incorporated 23
GlaxoSmithKline plc 24
Genentech, Inc. 25
Merck & Co., Inc. 26
Novartis AG 27
Astellas Pharma Inc. 28
4SC AG 29
Bionor Pharma ASA 30
Altor BioScience Corporation 31
Phoenix Biotechnology, Inc. 32
Cell Medica Limited 33
Chimerix, Inc. 34
Theraclone Sciences, Inc. 35
Microbiotix, Inc. 36
4-Antibody AG 37
VBI Vaccines 38
AIMM Therapeutics B.V. 39
Trellis Bioscience, Inc. 40
Vakzine Projekt Management GmbH 41
Spider Biotech S.r.l. 42
INAGEN ApS 43
Applied Immune Technologies Ltd 44
Redbiotec AG 45
Kadmon Corporation, LLC 46
Humabs BioMed SA 47
BioApex, s.r.o. 48
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Target 50
Assessment by Mechanism of Action 53
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 61
brincidofovir - Drug Profile 61
ASP-0113 - Drug Profile 63
Cytovir CMV - Drug Profile 64
maribavir - Drug Profile 65
TCN-202 - Drug Profile 67
ASP-0113 - Drug Profile 68
Donor-Derived CMV-pp65 Peptide-Specific T Cells - Drug Profile 69
letermovir - Drug Profile 70
RG-7667 - Drug Profile 71
Multi-Virus Specific T Cells - Drug Profile 72
CMV pp65 Specific T Cells - Drug Profile 73
T-Cell Immunotherapy - Drug Profile 74
CMV Streptacells - Drug Profile 75
Autologous T-Cell Therapy - Drug Profile 76
AVX-601 - Drug Profile 77
HCMV Specific CTL - Drug Profile 79
CMV Specific CTL - Drug Profile 81
Cytomegalovirus Vaccine - Drug Profile 82
CMV Specific T Cell Donor Lymphocyte - Drug Profile 83
filociclovir - Drug Profile 84
Multi-Virus Cytotoxic T Lymphocytes - Drug Profile 86
Small Molecule 1 For Human Cytomegalovirus Infection - Drug Profile 87
Small Molecule 2 For Human Cytomegalovirus Infection - Drug Profile 88
CMV TCR-001 - Drug Profile 89
CMV-MVA Triplex Vaccine - Drug Profile 90
V-160 - Drug Profile 91
CyMVectin - Drug Profile 92
Antiviral TCR-Ck - Drug Profile 93
Antiviral TCR-Ig - Drug Profile 94
4Ab-028 - Drug Profile 95
VPM-2001 - Drug Profile 96
RBT-301 - Drug Profile 97
CMV-345 - Drug Profile 98
SB-105 - Drug Profile 99
HB-101 - Drug Profile 100
Drug For Cytomegalovirus - Drug Profile 101
SB105-A10 - Drug Profile 102
Small Molecule 3 For Human Cytomegalovirus Infection - Drug Profile 104
Dual Active Cytomegalovirus (CMV)/Polyomavirus BK (BKV) Program - Drug Profile 105
4SC-302 - Drug Profile 106
MAb Against HCMV - Drug Profile 107
Cell Therapy For CMV - Drug Profile 108
Peptides For Cytomegalovirus Infections - Drug Profile 109
BA-368 - Drug Profile 110
CAP-CMV-001 - Drug Profile 111
RKP-00156 - Drug Profile 112
Drug for Infectious Disease - Drug Profile 113
CMV Vaccine - Drug Profile 114
Human Monoclonal Antibodies Program For CMV - Drug Profile 115
Nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile 116
TCRL Antibodies For CMV - Drug Profile 118
Small Molecules for Viral Infections - Drug Profile 119
Drug For Cytomegalovirus Infections - Drug Profile 120
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 121
Vacc-CMV - Drug Profile 122
Cell Therapy 2 For CMV - Drug Profile 123
Cell Therapy 3 For CMV - Drug Profile 124
Cytomegalovirus (HHV-5) Infections - Recent Pipeline Updates 125
Cytomegalovirus (HHV-5) Infections - Dormant Projects 140
Cytomegalovirus (HHV-5) Infections - Discontinued Products 142
Cytomegalovirus (HHV-5) Infections - Product Development Milestones 143
Featured News & Press Releases 143
Appendix 155
Methodology 155
Coverage 155
Secondary Research 155
Primary Research 155
Expert Panel Validation 155
Contact Us 156
Disclaimer 156
List of Tables
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2014 13
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 16
Number of Products under Development by Companies, H1 2014 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2014 19
Comparative Analysis by Late Stage Development, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Development, H1 2014 22
Comparative Analysis by Unknown Stage Development, H1 2014 23
Products under Development by Companies, H1 2014 24
Products under Development by Companies, H1 2014 (Contd..1) 25
Products under Investigation by Universities/Institutes, H1 2014 26
Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Incorporated, H1 2014 27
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline plc, H1 2014 28
Cytomegalovirus (HHV-5) Infections - Pipeline by Genentech, Inc., H1 2014 29
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co., Inc., H1 2014 30
Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H1 2014 31
Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc., H1 2014 32
Cytomegalovirus (HHV-5) Infections - Pipeline by 4SC AG, H1 2014 33
Cytomegalovirus (HHV-5) Infections - Pipeline by Bionor Pharma ASA, H1 2014 34
Cytomegalovirus (HHV-5) Infections - Pipeline by Altor BioScience Corporation, H1 2014 35
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology, Inc., H1 2014 36
Cytomegalovirus (HHV-5) Infections - Pipeline by Cell Medica Limited, H1 2014 37
Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix, Inc., H1 2014 38
Cytomegalovirus (HHV-5) Infections - Pipeline by Theraclone Sciences, Inc., H1 2014 39
Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix, Inc., H1 2014 40
Cytomegalovirus (HHV-5) Infections - Pipeline by 4-Antibody AG, H1 2014 41
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines, H1 2014 42
Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics B.V., H1 2014 43
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience, Inc., H1 2014 44
Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H1 2014 45
Cytomegalovirus (HHV-5) Infections - Pipeline by Spider Biotech S.r.l., H1 2014 46
Cytomegalovirus (HHV-5) Infections - Pipeline by INAGEN ApS, H1 2014 47
Cytomegalovirus (HHV-5) Infections - Pipeline by Applied Immune Technologies Ltd, H1 2014 48
Cytomegalovirus (HHV-5) Infections - Pipeline by Redbiotec AG, H1 2014 49
Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corporation, LLC, H1 2014 50
Cytomegalovirus (HHV-5) Infections - Pipeline by Humabs BioMed SA, H1 2014 51
Cytomegalovirus (HHV-5) Infections - Pipeline by BioApex, s.r.o., H1 2014 52
Assessment by Monotherapy Products, H1 2014 53
Number of Products by Stage and Target, H1 2014 56
Number of Products by Stage and Mechanism of Action, H1 2014 59
Number of Products by Stage and Route of Administration, H1 2014 61
Number of Products by Stage and Molecule Type, H1 2014 64
Cytomegalovirus (HHV-5) Infections Therapeutics - Recent Pipeline Updates, H1 2014 129
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2014 144
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..1), H1 2014 145
Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2014 146
List of Figures
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2014 13
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 15
Number of Products under Investigation by Universities/Institutes, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Products, H1 2014 22
Assessment by Monotherapy Products, H1 2014 53
Number of Products by Top 10 Target, H1 2014 54
Number of Products by Stage and Top 10 Target, H1 2014 55
Number of Products by Top 10 Mechanism of Action, H1 2014 57
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 58
Number of Products by Top 10 Route of Administration, H1 2014 60
Number of Products by Stage and Top 10 Route of Administration, H1 2014 61
Number of Products by Top 10 Molecule Type, H1 2014 62
Number of Products by Stage and Top 10 Molecule Type, H1 2014 63
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cytomegalovirus (HHV-5) Infections Overview 8
Therapeutics Development 9
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 9
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 10
Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 11
Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 14
Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 20
Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 22
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 23
Vical Incorporated 23
GlaxoSmithKline plc 24
Genentech, Inc. 25
Merck & Co., Inc. 26
Novartis AG 27
Astellas Pharma Inc. 28
4SC AG 29
Bionor Pharma ASA 30
Altor BioScience Corporation 31
Phoenix Biotechnology, Inc. 32
Cell Medica Limited 33
Chimerix, Inc. 34
Theraclone Sciences, Inc. 35
Microbiotix, Inc. 36
4-Antibody AG 37
VBI Vaccines 38
AIMM Therapeutics B.V. 39
Trellis Bioscience, Inc. 40
Vakzine Projekt Management GmbH 41
Spider Biotech S.r.l. 42
INAGEN ApS 43
Applied Immune Technologies Ltd 44
Redbiotec AG 45
Kadmon Corporation, LLC 46
Humabs BioMed SA 47
BioApex, s.r.o. 48
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Target 50
Assessment by Mechanism of Action 53
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 61
brincidofovir - Drug Profile 61
ASP-0113 - Drug Profile 63
Cytovir CMV - Drug Profile 64
maribavir - Drug Profile 65
TCN-202 - Drug Profile 67
ASP-0113 - Drug Profile 68
Donor-Derived CMV-pp65 Peptide-Specific T Cells - Drug Profile 69
letermovir - Drug Profile 70
RG-7667 - Drug Profile 71
Multi-Virus Specific T Cells - Drug Profile 72
CMV pp65 Specific T Cells - Drug Profile 73
T-Cell Immunotherapy - Drug Profile 74
CMV Streptacells - Drug Profile 75
Autologous T-Cell Therapy - Drug Profile 76
AVX-601 - Drug Profile 77
HCMV Specific CTL - Drug Profile 79
CMV Specific CTL - Drug Profile 81
Cytomegalovirus Vaccine - Drug Profile 82
CMV Specific T Cell Donor Lymphocyte - Drug Profile 83
filociclovir - Drug Profile 84
Multi-Virus Cytotoxic T Lymphocytes - Drug Profile 86
Small Molecule 1 For Human Cytomegalovirus Infection - Drug Profile 87
Small Molecule 2 For Human Cytomegalovirus Infection - Drug Profile 88
CMV TCR-001 - Drug Profile 89
CMV-MVA Triplex Vaccine - Drug Profile 90
V-160 - Drug Profile 91
CyMVectin - Drug Profile 92
Antiviral TCR-Ck - Drug Profile 93
Antiviral TCR-Ig - Drug Profile 94
4Ab-028 - Drug Profile 95
VPM-2001 - Drug Profile 96
RBT-301 - Drug Profile 97
CMV-345 - Drug Profile 98
SB-105 - Drug Profile 99
HB-101 - Drug Profile 100
Drug For Cytomegalovirus - Drug Profile 101
SB105-A10 - Drug Profile 102
Small Molecule 3 For Human Cytomegalovirus Infection - Drug Profile 104
Dual Active Cytomegalovirus (CMV)/Polyomavirus BK (BKV) Program - Drug Profile 105
4SC-302 - Drug Profile 106
MAb Against HCMV - Drug Profile 107
Cell Therapy For CMV - Drug Profile 108
Peptides For Cytomegalovirus Infections - Drug Profile 109
BA-368 - Drug Profile 110
CAP-CMV-001 - Drug Profile 111
RKP-00156 - Drug Profile 112
Drug for Infectious Disease - Drug Profile 113
CMV Vaccine - Drug Profile 114
Human Monoclonal Antibodies Program For CMV - Drug Profile 115
Nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile 116
TCRL Antibodies For CMV - Drug Profile 118
Small Molecules for Viral Infections - Drug Profile 119
Drug For Cytomegalovirus Infections - Drug Profile 120
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 121
Vacc-CMV - Drug Profile 122
Cell Therapy 2 For CMV - Drug Profile 123
Cell Therapy 3 For CMV - Drug Profile 124
Cytomegalovirus (HHV-5) Infections - Recent Pipeline Updates 125
Cytomegalovirus (HHV-5) Infections - Dormant Projects 140
Cytomegalovirus (HHV-5) Infections - Discontinued Products 142
Cytomegalovirus (HHV-5) Infections - Product Development Milestones 143
Featured News & Press Releases 143
Appendix 155
Methodology 155
Coverage 155
Secondary Research 155
Primary Research 155
Expert Panel Validation 155
Contact Us 156
Disclaimer 156
List of Tables
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2014 13
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 16
Number of Products under Development by Companies, H1 2014 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2014 19
Comparative Analysis by Late Stage Development, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Development, H1 2014 22
Comparative Analysis by Unknown Stage Development, H1 2014 23
Products under Development by Companies, H1 2014 24
Products under Development by Companies, H1 2014 (Contd..1) 25
Products under Investigation by Universities/Institutes, H1 2014 26
Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Incorporated, H1 2014 27
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline plc, H1 2014 28
Cytomegalovirus (HHV-5) Infections - Pipeline by Genentech, Inc., H1 2014 29
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co., Inc., H1 2014 30
Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H1 2014 31
Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc., H1 2014 32
Cytomegalovirus (HHV-5) Infections - Pipeline by 4SC AG, H1 2014 33
Cytomegalovirus (HHV-5) Infections - Pipeline by Bionor Pharma ASA, H1 2014 34
Cytomegalovirus (HHV-5) Infections - Pipeline by Altor BioScience Corporation, H1 2014 35
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology, Inc., H1 2014 36
Cytomegalovirus (HHV-5) Infections - Pipeline by Cell Medica Limited, H1 2014 37
Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix, Inc., H1 2014 38
Cytomegalovirus (HHV-5) Infections - Pipeline by Theraclone Sciences, Inc., H1 2014 39
Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix, Inc., H1 2014 40
Cytomegalovirus (HHV-5) Infections - Pipeline by 4-Antibody AG, H1 2014 41
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines, H1 2014 42
Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics B.V., H1 2014 43
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience, Inc., H1 2014 44
Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H1 2014 45
Cytomegalovirus (HHV-5) Infections - Pipeline by Spider Biotech S.r.l., H1 2014 46
Cytomegalovirus (HHV-5) Infections - Pipeline by INAGEN ApS, H1 2014 47
Cytomegalovirus (HHV-5) Infections - Pipeline by Applied Immune Technologies Ltd, H1 2014 48
Cytomegalovirus (HHV-5) Infections - Pipeline by Redbiotec AG, H1 2014 49
Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corporation, LLC, H1 2014 50
Cytomegalovirus (HHV-5) Infections - Pipeline by Humabs BioMed SA, H1 2014 51
Cytomegalovirus (HHV-5) Infections - Pipeline by BioApex, s.r.o., H1 2014 52
Assessment by Monotherapy Products, H1 2014 53
Number of Products by Stage and Target, H1 2014 56
Number of Products by Stage and Mechanism of Action, H1 2014 59
Number of Products by Stage and Route of Administration, H1 2014 61
Number of Products by Stage and Molecule Type, H1 2014 64
Cytomegalovirus (HHV-5) Infections Therapeutics - Recent Pipeline Updates, H1 2014 129
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2014 144
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..1), H1 2014 145
Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2014 146
List of Figures
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2014 13
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 15
Number of Products under Investigation by Universities/Institutes, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Products, H1 2014 22
Assessment by Monotherapy Products, H1 2014 53
Number of Products by Top 10 Target, H1 2014 54
Number of Products by Stage and Top 10 Target, H1 2014 55
Number of Products by Top 10 Mechanism of Action, H1 2014 57
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 58
Number of Products by Top 10 Route of Administration, H1 2014 60
Number of Products by Stage and Top 10 Route of Administration, H1 2014 61
Number of Products by Top 10 Molecule Type, H1 2014 62
Number of Products by Stage and Top 10 Molecule Type, H1 2014 63
